US Stock Market Move | Withdrawal of experimental drug riluzole application in the EU market leads to a 21% drop in Biohaven (BHVN.US) stock.
On Friday, Biohaven (BHVN.US) plunged during trading hours, with the decline widening to 21% at one point, and is now trading at $20.62.
On Friday, Biohaven (BHVN.US) plunged during trading, with the decline reaching 21% at one point, and is now trading at $20.62. On the news front, the company has withdrawn its application for the experimental drug Troriluzole in the EU market. This drug has been studied as a potential treatment for Machado-Joseph disease, OCD, and glioblastoma.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
